PP07-4 Lorcaserin Decreases Activation of Attention-Related Brain Centers in Response to Food Cues during a Four-Week-Long Randomized, Placebo-Controlled, Double-Blinded Clinical Trial

Program: Abstracts - Orals, Poster Previews, and Posters
Session: PP07-Predictors of Weight Gain and Disease
Friday, April 1, 2016: 11:30 AM-11:45 AM
Room 160 (BCEC)

Poster Board FRI 600
Olivia M. Farr*1, Jagriti Upadhyay2, Anna Gavrieli3, Hannah Mathew3, Maria T Vamvini4, Michelle Camp3, Harper Kaye3, Nikolaos Spyrou3, Anastasia Koniaris3, Holly Kilim3, Alexandra Srnka3, Alexandra Migdal5 and Christos S. Mantzoros6
1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Harvard Medical School/ Beth Israel Deaconess Medical Center, Jamaica Plain, MA, 3Harvard Medical School/ Beth Israel Deaconess Medical Center, 4Mount Auburn Hospital, Cambridge, MA, 5Beth Israel Deaconess Medical Center, Boston, MA, 6BIDMC, Harvard, Boston, MA
Lorcaserin is a 5HT-2c receptor agonist effective in treating obesity. While studies in rodents have shown that lorcaserin acts in the brain to exert its weight reducing effects, this has not yet been confirmed in humans. Also, which brain centers may be activated in humans remains unknown. We performed a randomized, placebo-controlled, double-blind trial with 48 obese participants to study the effects of lorcaserin on the brain using functional magnetic resonance imaging (fMRI) after 1 week and 4 weeks of therapy. We found decreased brain activations in the parietal and visual cortices in response to highly palatable food cues at 1 week in the fasting state and in the parietal cortex in response to any food cues at 4 weeks after a standardized meal. Decreases in weight and caloric intake correlated with activations in parietal and visual cortices to highly desirable food cues at baseline. Additionally, in a whole brain regression analysis, we observed that activations of amygdala to highly desirable food cues at baseline correlated to weight lost at 4 weeks. Altogether, this data suggests that lorcaserin exerts its weight reducing effects by decreasing attention-related brain activations to food cues, including the parietal and visual cortices and/or amygdala. Results from the regression analysis suggest that lorcaserin is of particular benefit to individuals who are emotional eaters. These data need to be confirmed and extended by future studies.

Nothing to Disclose: OMF, JU, AG, HM, MTV, MC, HK, NS, AK, HK, AS, AM, CSM

*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting/pr-resources-for-endo

Sources of Research Support: Eisai Investigator-Initiated Study; NIH 5T32HD052961; NIH UL1 RR025758